LEO Pharma has gained marketing authorisation from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for ...

LEO Pharma has announced that its Anzupgo (delgocitinib) cream has been approved by the Medicines and Healthcare Products ...

LEO Pharma A/S, a global leader in medical dermatology, announced that Swissmedic, Switzerland’s national regulatory agency for approving and overseeing therapeutic products, has granted marketing ...

4-7 LEO Pharma A/S, a global leader in medical dermatology ... has granted marketing approval for Anzupgo ® (delgocitinib) cream. The indication is for the treatment of moderate to severe ...

4-7 LEO Pharma A/S, a global leader in medical dermatology, today announced that Swissmedic, Switzerland’s national regulatory agency for approving and overseeing therapeutic products, has granted ...

1 Delgocitinib cream is now the first approved topical pan-Janus kinase (JAK) inhibitor treatment specifically for adults with moderate to severe CHE. 1 The authorisation introduces a new treatment ...